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Abstract
©2016 AACR.Purpose: Small cell lung cancer (SCLC) is a highly aggressive disease representing
12% to 13% of total lung cancers, with median survival of <2 years. No targeted therapies have
proven effective in SCLC. Although most patients respond initially to cytotoxic chemotherapies,
resistance  rapidly  emerges,  response  to  second-line  agents  is  limited,  and  dose-limiting
toxicities (DLT) are a major issue. This study performs preclinical evaluation of a new compound,
STA-8666, in SCLC. Experimental Design: To avoid DLT for useful cytotoxic agents, the recently
developed drug STA-8666 combines a chemical moiety targeting active HSP90 (concentrated in
tumors) fused via cleavable linker to SN38, the active metabolite of irinotecan. We compare
potency and mechanism of action of STA-8666 and irinotecan in vitro and in vivo. Results: In two
SCLC xenograft and patient-derived xenograft models, STA-8666 was tolerated without side
effects up to 150 mg/kg. At this dose, STA-8666 controlled or eliminated established tumors
whether used in a first-line setting or in tumors that had progressed following treatment on
standard first- and second-line agents for SCLC. At 50 mg/kg, STA-8666 strongly enhanced the
action of carboplatin. Pharmacokinetic profiling confirmed durable STA-8666 exposure in tumors
compared with irinotecan. STA-8666 induced a more rapid, robust, and stable induction of cell-
cycle  arrest,  expression  of  signaling  proteins  associated  with  DNA damage  and  cell-cycle
checkpoints, and apoptosis in vitro and in vivo, in comparison with irinotecan. Conclusions:
Together, these results strongly support clinical development of STA-8666 for use in the first- or
second-line setting for SCLC.
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